STaMINA Long-term Follow-up: Post–Autologous Hematopoietic Cell Transplantation Strategies for Multiple Myeloma

May 29-31, 2020; Online at meetings.asco.org/am
For newly diagnosed patients with multiple myeloma, adding RVD consolidation or a second ASCT to initial ASCT plus lenalidomide maintenance did not improve PFS or OS at 6 years for those with no progression at 38 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue